• Unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence (the molecule which tells cells what to build) which is coded for a disease specific antigen, once produced within the body, the antigen is recognised by the immune system, preparing it to fight the real thing
• RNA vaccines are faster and cheaper to produce than traditional vaccines, and a RNA based vaccine is also safer for the patient, as they are not produced using infectious elements
• Production of RNA vaccines is laboratory based, and the process could be standardised and scaled, allowing quick responses to large outbreaks and epidemics

• Safety: RNA vaccines are not made with pathogen particles or inactivated pathogen, so are non-infectious. RNA does not integrate itself into the host genome and the RNA strand in the vaccine is degraded once the protein is made.
• Efficacy: early clinical trial results indicate that these vaccines generate a reliable immune response and are well-tolerated by healthy individuals, with few side effects.
• Production: vaccines can be produced more rapidly in the laboratory in a process that can be standardised, which improves responsiveness to emerging outbreaks.

minialu22 说:

长知识了

点击展开...

Aidemengdun 说:

Summary

Unlike a normal vaccine, RNA vaccines work by introducing an mRNA sequence (the molecule which tells cells what to build) which is coded for a disease specific antigen, once produced within the body, the antigen is recognised by the immune system, preparing it to fight the real thing
RNA vaccines are faster and cheaper to produce than traditional vaccines, and a RNA based vaccine is also safer for the patient, as they are not produced using infectious elements
Production of RNA vaccines is laboratory based, and the process could be standardised and scaled, allowing quick responses to large outbreaks and epidemics



Benefits
Benefits of mRNA vaccines over conventional approaches are1:


Safety: RNA vaccines are not made with pathogen particles or inactivated pathogen, so are non-infectious. RNA does not integrate itself into the host genome and the RNA strand in the vaccine is degraded once the protein is made.
Efficacy: early clinical trial results indicate that these vaccines generate a reliable immune response and are well-tolerated by healthy individuals, with few side effects.
Production: vaccines can be produced more rapidly in the laboratory in a process that can be standardised, which improves responsiveness to emerging outbreaks.

我是相信这个疫苗的可靠性。
Pfizer and Moderna 都是mRNA类型疫苗，几个关键点。只要一旦突破技术点，几个大厂只不过是先后做成功了。

这次的mRNA确实是疫苗的革新，以后不用灭活这种低效率的疫苗方式了.

Source from https://www.phgfoundation.org/briefing/rna-vaccines

点击展开...

comeback 说:

只要能抵御病毒造福人类就是好事。。。

点击展开...

清月莲花 说:

总算有盼头了！

点击展开...

lovemapleleaf 说:

这个疫苗比辉瑞的好，不用2次打，保存也容易很多，零下20度就可以，不像辉瑞疫苗要-70度

希望能尽早上市

点击展开...

lovemapleleaf 说:

这个疫苗比辉瑞的好，不用2次打，保存也容易很多，零下20度就可以，不像辉瑞疫苗要-70度

希望能尽早上市

点击展开...

周雅 说:

辉瑞周三宣布，辉瑞/BioNTech疫苗的最终疗效报告显示出95%有效性，高于Moderna的94.5%。 不过储存条件比较苛刻，必须在零下70摄氏度储存和运输，这一温度远低于竞争对手Moderna 2-8摄氏度的储存要求， Moderna新冠疫苗的保质期更长，在冰箱温度下可维持30天。

了解能够安全储存辉瑞研发的新冠疫苗，美国各州、城市和医院开始争抢超低温冷藏设备。冰箱制造商警告称，冷冻柜开始出现供不应求，供货要等待数月之久。

到2020年底，Moderna预计将有大约2000万剂mRNA-1273供应美国。2021年，该公司有望在全球生产5亿至10亿剂mRNA-1273。

辉瑞预计今年仍将生产5000万剂疫苗，到2021年将达到13亿剂。

点击展开...